Characterization of primaquine imidazolidin-4-ones with antimalarial activity by electrospray ionization-ion trap mass spectrometry by Nuno Vale et al.
Aa
f
d
p
d
u
©
K
1
p
f
y
a
m
t
q
o
t
a
g
S
t
[
h
1
dAvailable online at www.sciencedirect.com
International Journal of Mass Spectrometry 270 (2008) 81–93
Characterization of primaquine imidazolidin-4-ones with antimalarial
activity by electrospray ionization-ion trap mass spectrometry
Nuno Vale a, Rui Moreira b, Paula Gomes a,∗
a Centro de Investigac¸a˜o em Quı´mica da Universidade do Porto, Departamento de Quı´mica, Faculdade de Cieˆncias,
Universidade do Porto, R. Campo Alegre 687, P-4169-007 Porto, Portugal
b Centro de Estudos de Cieˆncias Farmaceˆuticas, Faculdade de Farma´cia,
Universidade de Lisboa, Av. Prof. Gama Pinto, P-1649-019 Lisboa, Portugal
Received 19 November 2007; accepted 5 December 2007
Available online 14 December 2007
bstract
The extensive characterization by electrospray ionization-ion trap mass spectrometry (ESI-MSn) of 20 imidazolidin-4-ones derived from the
ntimalarial primaquine was well obtained. These compounds are being under investigation as potential antimalarials, as they have been previously
ound to be active against rodent P. berghei malaria and to be highly stable under physiological conditions. Experiments by collision-induced
issociation (CID) in the nozzle-skimmer region or by tandem-MS have shown the title compounds to be remarkably stable. Mechanisms are
roposed to explain the major fragmentations observed in ESI-MSn experiments. Overall, this work represents an unprecedented contribution to a
eeper insight into imidazolidin-4-one antimalarials based on a classic 8-aminoquinolinic scaffold. Data herein reported and discussed may be an
seful guide for future studies on therapeutically relevant molecules possessing either the 8-aminoquinoline or the imidazolidin-4-one motifs.
2007 Elsevier B.V. All rights reserved.
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. Introduction
The diverse analytical methods focused on the antimalarial
rimaquine (PQ, 1, Scheme 1) or its analogues have been so
ar targeted at pharmacokinetics studies and metabolite anal-
sis [1–9] or isomer separation/characterization [10,11]. The
pplication of molecular modeling studies associated to voltam-
etric techniques showed to be an important way to understand
he redox mechanism of electro-active drugs where amino-
uinolines (AQs) such as PQ are included [7]. Two classes
f AQs were investigated by infrared spectrometry to assess
heir geometry and coordination ability [6]. UV absorption
nd circular dichroism (CD) have also been used to investi-
ate interactions between heparin and several quinolines [6].
tudies with HPLC are also currently used to characterizeherapeutically relevant AQs, including PQ and its metabolites
1–3]. Other analytical tools to study PQ and its derivatives
ave included fast atom bombardment mass spectral analysis
∗ Corresponding author. Tel.: +351 220402563; fax: +351 220402659.
E-mail address: pgomes@fc.up.pt (P. Gomes).
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f three new PQ oxidation products [4] or enantioselective cap-
llary electrophoresis for the simultaneous determination of PQ
nd its main metabolite, carboxyprimaquine, in rat liver mito-
hondrial fraction [5]. Supercritical fluid chromatography–mass
pectrometry (SFC–MS) was used to achieve shorter analysis
imes while having good resolution between PQ (free base),
Q diphosphate and the positional isomer quinocide, as well
s to elucidate additional information about differences in their
S fragmentation patterns [8]. PQ and its isomers have also
een identified by liquid chromatography–mass spectrometry
LC–MS) [10].
Electrospray ionization-mass spectrometry (ESI-MS) analy-
is, introduced by Yamashita and Fenn [12a,b], was described for
he identification of NPC 1161, another antimalarial 8-AQ, and
ts metabolites in biological samples [9]. ESI-MS techniques
re relevant in many research and development (R&D) areas
13–19], from food chemistry to the pharmaceutical industry
20–37]. Detailed structural information on drugs and related
olecules can be obtained by resorting to cone voltage fragmen-
ation with single MS instrumentation, to collisionally induced
issociation (CID) with triple quadrupole MS instruments, to
Sn techniques using quadrupole ion-trap instrumentation or
82 N. Vale et al. / International Journal of Mass Spectrometry 270 (2008) 81–93
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3cheme 1. Synthetic route to imidazolidin-4-one derivatives of PQ [40]: (i) B
.t.; 30% aq. Na2CO3 until pH 10, extraction with CHCl3; (iii) R2(C O)R3, mo
o time-of-flight mass spectrometry (ToF-MS) [31,32,35]. ESI-
Sn studies of antimalarial compounds as bisthiazolium or
uinolines can be found on reports by Nicolas et al. [38] or
myth et al. and O’Donnell et al. [34,39], respectively. However,
SI-MS studies contributing to the development of antimalar-
als are scarce. Over the past few years, our research group
as been working on imidazolidin-4-one derivatives of PQ
s potential highly bioavailable antimalarials [40–42]. These
midazolidin-4-ones (4, Scheme 1) are stable at physiological pH
nd temperature, both in isotonic buffer and in human plasma,
videncing a weak conversion into their PQ -aminoamide pre-
ursors (3, Scheme) with half-lives ranging from 9 to 30 days
41,42]. Moreover, these imidazolidin-4-one derivatives of PQ
isplayed gametocytocidal activity comparable or superior to
hat of the parent drug [41].
We now wish to report the characterization of 20 PQ-derived
midazolidin-4-ones 4 (Table 1) by ESI-MSn techniques. This
ontributes to a deeper insight into the properties of these bio-
b
e
b
c
able 1
Q and derived imidazolidin-4-ones studied; average m/z values for the main species
lso given for comparison
ompound R1 R2 R3
.1 –H –CH3 –CH3
.2 –CH3 –CH3 –CH3
.3 –CH(CH3)2 –CH3 –CH3
.4 –CH2Ph –CH3 –CH3
.5 –CH2CH(CH3)2 –CH3 –CH3
.6 –CH(CH3)CH2CH3 –CH3 –CH3
.7 –CH(CH3)2 –(CH2)4–
.8 –CH(CH3)2 –(CH2)5–
.9 –CH(CH3)2 –(CH2)6–
.10 –CH(CH3)2 –(CH2)2CH(CH3)(CH2)2–
.11 –H –(CH2)2CH(CH3)(CH2)2–
.12 –CH3 –(CH2)2CH(CH3)(CH2)2–
.13 –CH3 –(CH2)6–
.14 –CH2CH(CH3)2 –(CH2)6–
.15 –CH(CH3)CH2CH3 –(CH2)6–
.16 –H –(CH2)5–
.17 –CH2CH(CH3)2 –(CH2)5–
.18 –CH(CH3)CH2CH3 –(CH2)5–
.19 –CH3 –(CH2)4–
.20 –CH2Ph –(CH2)4–
– – –
.2 –CH3 – –
a Sodium adducts were never observed in the full-MS spectra of primaquine.OH + DCCI/HOBt or BocAAOSu (see text), DCM, 0 ◦C → r.t.; (ii) neat TFA,
ar sieves, refluxing MeOH.
ogically relevant 8-AQs, through knowledge of their stability
nd fragmentation mechanisms under the gas-phase conditions
f the ESI-MSn experiments.
. Experimental
.1. Chemical synthesis
The synthesis and spectral (NMR, HRMS) characterization
f 14 out of the 20 imidazolidin-4-ones 4 covered by the present
tudy have been reported elsewhere [40]. The procedure for
he initial condensation of PQ with a Boc-protected amino acid
BocAAOH) in dichloromethane (DCM) was slightly changed
ith respect to our previous report [40], as reaction times can
e dramatically reduced through utilization of the succinimide
ster of the amino acid, instead of using a dicyclohexylcar-
odiimide (DCCI)/1-hydroxybenzotriazole (HOBt)-mediated
ondensation. The six new derivatives were obtained by the
detected in the full-MS spectral analysis of compounds 1, 3.2 and 4.1–4.20 are
MW (g mol−1) m/z [M + H]+ m/z [M + Na]+
356.46 357.87 379.67
370.49 371.93 393.60
398.45 399.93 422.00
446.58 448.47 470.07
412.57 414.07 436.06
412.57 414.07 436.33
424.58 425.93 447.80
438.61 439.87 461.87
452.63 453.93 475.87
452.63 453.93 476.33
410.55 412.33 433.80
424.58 425.80 448.07
424.58 425.67 447.93
466.66 467.87 490.93
466.66 468.00 490.20
396.53 397.93 419.87
452.63 453.93 475.87
452.63 453.93 476.07
396.53 397.93 420.07
472.62 474.07 495.93
259.35 260.80 –a
330.42 331.23 354.00
N.V
ale
et
al./InternationalJo
u
rn
al
ofM
assSpectro
m
etry
270(2008)81–93
83
Table 2
Main species (relative abundance ≥20%) detected in the analyses in the nozzle-skimmer region
Species Vs CID Compounds on whose spectra the species was observed
[M + H]+ and/or [M + Na]+ 70 4.2 4.3 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 1
80 4.2 4.3 4.4 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 1
90 4.2 4.3 4.4 4.6 4.7 4.8 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.20 1
100 4.2 4.3 4.4 4.7 4.8 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 1
[M2 + H]+ and/or [M2 + Na]+ 70 4.4 4.5 4.11 4.14 4.15 4.16 4.20
80 4.4 4.8 4.9 4.11 4.14 4.15 4.16 4.20
90 4.5 4.8 4.9 4.11 4.14 4.15 4.16 4.19 4.20
100 4.4 4.5 4.8 4.9 4.11 4.14 4.15 4.16 4.18 4.19 4.20
[M3 + H]+ 70
80
90 4.19
100 4.19
[5 + H]+, quasi-molecular ion
of MAQ (m/z = 175)
70 4.1 4.2 4.3 4.4 4.5 4.8 4.9 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 1
80 4.1 4.2 4.3 4.4 4.5 4.8 4.9 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 1
90 4.2 4.3 4.4 4.5 4.8 4.9 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 1
100 4.2 4.3 4.4 4.8 4.9 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 1
[DHQ + H]+, quasi-molecular ion of
7,8-dihydroquinoline (m/z = 132)
70 4.1 4.2 4.3 4.4 4.5 4.16 4.19 1
80 4.1 4.2 4.3 4.4 4.5 4.8 4.11 4.12 4.13 4.16 4.19 1
90 4.1 4.2 4.3 4.5 4.7 4.8 4.9 4.11 4.12 4.13 4.15 4.16 4.19 1
100 4.1 4.2 4.3 4.5 4.7 4.8 4.9 4.11 4.12 4.13 4.15 4.16 4.19 1
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ame procedure and were synthesized in goods yields from the
orresponding -aminoamides (3, Scheme 1) by refluxing with
n excess of the appropriate ketone in methanol, in the pres-
nce of triethylamine and molecular sieves. The structures of
he new compounds were confirmed by 1H and 13C NMR, and
lso by HRMS using the MALDI-TOF technique (cf. Supporting
nformation).
.2. ESI-MSn analysis
ESI-MSn studies on compounds 4.1–4.20 (Table 1) were
chieved using a Finnigan Surveyor LCQ DECA XP MAX
uadrupole ion trap mass spectrometer, utilizing electrospray
onization (ESI). Methanolic solutions of the compounds, con-
aining 0.1% acetic acid, were infused into the ESI probe at a
ate of 3L min−1. Inclusion of methanol to prepare samples
as necessary to obtain good electrospray behavior [26]. In the
SI source, nitrogen sheath gas flow was maintained at 20 psi,
he capillary temperature was set to 275 ◦C and the spray volt-
ge was set to 5 kV. Capillary voltage was of 15 V and tube
ens voltage was of 30 V. All spectra were obtained in positive
ode and data were collected and analyzed by using the Xcal-
bur software developed by ThermoFinnigan. To induce sample
ragmentation, two processes were used: collision-induced dis-
ociation (CID) in the nozzle-skimmer region and tandem-MS.
n the first process, fragmentation is induced by colliding sam-
le ions with the background gas in the intermediate-pressure
egion of the ESI interface. This region is also called “nozzle-
a
o
m
m
Scheme 2. Main MS/MS fragmentation of compoundsass Spectrometry 270 (2008) 81–93
kimmer” and gas pressure is about 10−1 mbar. Increasing the
oltage between the nozzle and the skimmer (Vs CID) increases
he kinetic energy of the ions passing through this region. This
aises the energy of collision between the ions and background
as, eventually causing fragmentation [43].
Tandem-MS or MS/MS occurs at the high vacuum region
f the mass analyzer; the ion of interest is isolated within the
on trap by ejecting all other ions out of the trap. Then, this ion
s accelerated, by applying a high-frequency AC voltage, and
ollides with a collision gas. The fragmentation ions generated
re then detected by a mass scan [43]. The collision energy
eeded to achieve optimum fragmentation efficiency has been
hown to follow a linear correlation with m/z. The normalized
ollision energy (NCE) principle automatically compensates for
his mass dependency [44].
Three types of fragmentation experiments were conducted.
he first was carried out on the nozzle-skimmer region where
he Vs CID parameter was varied between 70 and 100 V. The
valuation of the influence of the voltage in-source on the
ragmentation patterns provides a means to distinguish stable
dducts from unstable species.
The second experiment was done by tandem-MS and was
haracterized by varying the NCE levels at 10, 20, 30 or 40%.
his was done to establish the optimal NCE value that would
llow, through MS2 spectra, to analyze the structural stability
f the sample, as this parameter has been used to predict drug
etabolites at given NCE values as recommended by the MS
anufacturer (25 or 30%) [32,44].
4 at normalized collision energies of 30 and 40%.
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The third experiment was also done by tandem-MS at a
xed NCE value of 30%, for subsequent MSn analysis of the
ain fragment generated on the previous MSn−1 fragmentation
n = 3, 4). MS2 fragmentation was done on the quasi-molecular
on ([M + H]+) observed in the corresponding full-MS spectrum.
his was not necessarily the base peak, as imidazolidin-4-ones
were quite prone to form sodium adducts ([M + Na]+ species)
hat were frequently the base peaks in full-MS spectra.
. Results and discussion
.1. Experiments in the nozzle-skimmer region
Spectra were obtained at four different voltages, 70, 80, 90
nd 100 V. These can be regarded as high values (100 V is the
aximum reached by the spectrometer) that were deliberately
hosen to test compound resistance against bond disruption
nder highly fragmentative conditions. Results compiled in
able 2 demonstrate that compounds 4 were mainly detected
s [M + H]+ and/or [M + Na]+ ions. The two major occurring
ragmentations led to observation of peaks at m/z 175 and m/z
32 that were respectively associated to the quasi-molecular
c
p
u
o
Fig. 1. Fragmentation spectra for compound 4.20 on tass Spectrometry 270 (2008) 81–93 85
ons ([M + H]+) of 6-methoxy-8-aminoquinoline (MAQ, 5 on
cheme 2) and of, probably, 7,8-dihydroquinoline (DHQ,
W = 131 g mol−1) that can be generated from any of com-
ounds 4. DHQ has also been previously found as the major
roduct of MS2 fragmentation of nicotine [34].
Some of the imidazolidin-4-ones, such as 4.1 and 4.5 gave
ise to complex spectra, presenting a high number of peaks
nd not showing either the imidazolidin-4-one quasi-molecular
on [M + H]+ or its sodium adduct [M + Na]+ at any of the
our voltages employed, which was interpreted as an out-
ome of their higher instability at the analysis conditions
mployed.
The above situation was exceptional, as the majority of com-
ounds 4 generated relatively clean spectra with no increase
n fragmentative phenomena at higher voltages. An example
s that of compound 4.20 whose spectrum is mainly com-
osed by peaks due to the following ions: [M + H]+, [M + Na]+,
M2 + Na]+ and by a peak at m/z = 186 due to fragment
yclo[(CH2)4C+]–N CH–CH2Ph (see Section 3.3). Fig. 1 dis-
lays the spectra obtained for 4.20 at the four different voltages
sed, showing that increasing the potential provokes a decrease
n peak intensity at m/z = 186, but favors the in-source forma-
he skimmer-CID region at 70, 80, 90 and 100 V.
86
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Table 3
MS2 data obtained at varying normalized collision energies
Original compound
(MW/g mol−1)
Base-peak observed (m/z) Relative abundance of the
original species at NCE 30%
Relative abundance of
MAQ (5) at NCE 30%a
Normalized collision energy (%) for MS/MS
10 20 30 40
4.1 (356.46) 357.19 357.19 183.15 183.15 23.86 7.10
4.2 (370.49) 371.20 371.20 197.13 197.13 11.83 10.52
4.3 (398.45) 399.20 399.20 225.13 225.13 15.03 11.31
4.4 (446.58) 447.12 447.18 273.15 273.15 24.22 3.83
4.5 (412.57) 413.27 413.33 239.20 239.20 30.23 6.34
4.6 (412.57) 413.27 413.27 239.20 239.20 27.93 7.44
4.7 (424.58) 425.29 425.29 251.18 251.18 27.89 4.31
4.8 (438.61) 439.27 439.27 265.16 265.16 11.63 7.48
4.9 (452.63) 453.30 453.30 279.20 279.20 18.00 12.28
4.10 (452.63) 453.20 453.20 279.27 279.13 31.80 8.12
4.11 (410.55) 411.20 411.20 237.33 237.33 23.28 7.12
4.12 (424.58) 425.22 425.22 251.25 251.25 18.36 8.62
4.13 (424.58) 425.22 425.22 251.25 251.18 28.98 10.80
4.14 (466.66) 467.27 467.27 293.27 293.27 23.80 14.49
4.15 (466.66) 467.33 467.33 293.33 293.20 44.06 9.26
4.16 (396.53) 398.20 398.20 224.27 224.27 23.50 13.75
4.17 (452.63) 453.24 453.24 279.27 279.20 33.06 6.28
4.18 (452.63) 453.27 453.33 279.27 279.20 22.74 8.31
4.19 (396.53) 397.20 397.20 223.20 223.13 19.54 4.91
4.20 (472.62) 473.20 473.20 299.27 299.20 18.27 1.63
1 ((259.35) 260.07 260.00 243.24 243.17 0.00 34.86
3.2 (330.42) 331.23 331.23 157.19 157.06 21.37 57.59
a Fragment common to all compounds studied, with m/z ([M + H]+) = 175.
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ion of the [M2 + Na]+ adduct. Peak intensity for ions [M + H]+
nd [M + Na]+ are similar, but there is a slight inversion on rela-
ive intensity when the potential is increased. The fragmentation
ehavior of compound 4.20 under these conditions suggests that
ts structure is quite stable. Interestingly, this compound has been
reviously characterized as highly stable in human plasma at
hysiological pH and temperature, where it remains intact after
2 h of incubation [41,42].
Another example of remarkable stability under the condi-
ions of the ESI-MS analysis refers to compound 4.7, whose
ragmentation behavior in-source is slightly different from that
f 4.20. In the case of 4.7, voltage increase favors the formation
f the [M + Na]+ ion, whereas the number and type of fragments
emain unchanged (not shown). In fact, all imidazolidin-4-ones
erived from the amino acid valine were seen to be stable towards
n-source fragmentation, as further illustrated by the behavior
f compound 4.10 that does not even originate the fragments
t m/z = 175 and 132, currently observed for the generality of
ompounds 4 (Table 2).
Finally, it must be outlined that acetone-derived imidazolidin-
-ones (4.1–4.6), especially smaller ones, were clearly more
fragmentable” than those derived from cyclic ketones. Again,
t is interesting to notice that a similar stability pattern was
bserved for compounds 4 under totally different conditions,
amely, towards hydrolysis at physiological pH and temperature
41,42].
a
I
v
h
cheme 3. Fragmentations of compounds 4 in the MS3 mode at 30% NCE: (A) mai
erived from 4.1, 4.2, 4.13 and 4.16.ass Spectrometry 270 (2008) 81–93 87
Both the parent drug (PQ, 1) and the linear -aminoamide
recursor of Ala-derived imidazolidin-4-ones 4.2, 4.12, 4.13,
.19, compound 3.2 (Table 1), were subject of an identical study
n the nozzle-skimmer region. We could observe that the in-
ource behavior of both 1 and 3.2 were quite different from
hose of compounds 4, in the sense that both compounds gave
ise to much “dirtier” spectra and to significant signal carry-over
etween analyses (data not shown). This was interpreted, respec-
ively, as due to higher compound instability in the course of the
S analysis and to the fact that both compounds have a terminal
rimary amino group that can strongly attach to the fused silica
apillary. This latter fact turned comparisons between linear and
yclic compounds out of significance.
.2. ESI-MS2 analysis at varying NCE values
This set of experiments was aimed at the determination of
he influence of the normalized collision energy on the mech-
nism and extension of fragmentation of compounds 4.1–4.20.
ompounds 1 and 3.2 were included for comparison.
Many reports in the literature have been devoted to character-
zation of different compounds by tandem-MS, with particular
ttention to the conditions of collision, i.e., NCE values [45–49].
n the majority of those reports, 25% was used as the standard
alue for NCE in drug fragmentation studies. In our case, we
ave raised the NCE up to 40% to fully characterize the behav-
n fragmentation pathway; (B) additional relevant fragmentations on structures
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or of imidazolidin-4-ones 4. As shown by data in Table 3, at
CE values of 10 and 20%, the base-peak was still the quasi-
olecular ion [M + H]+, whereas at 30 and 40%, the base-peak
ccurs, for all cases, at m/z = m/z[M + H]+ − 174. This is due
o loss of the 6-methoxy-8-aminoquinoline core (MAQ, 5), as
epicted in Scheme 2.
The fragmentation pathway proposed in Scheme 2, involv-
ng elimination of a primary amine (MAQ, 5), is corroborated
y a previous LC/ESI-MS characterization of primaquine (1)
nd its major contaminant, quinocide, carried out by Brondz
t al. [10]. Other examples where MS2 fragmentation leads
o cleavage of a C–N bond with amine release are mostly
ound for tertiary amines, as these have C–N bond dissocia-
ion energies (BDE) lower than those of their secondary amine
ounterparts [31]. For instance, the ESI-MS behavior of thera-
eutically relevant tertiary amines has been described by Smyth
f
f
t
a
cheme 4. Hypothetical pathways leading to loss of NH3 (A) or CH4 (B) from speci
nd Y = –(CH2)2–CH(CH3)–(CH2)2–].ass Spectrometry 270 (2008) 81–93
nd co-workers to involve fragmentation to smaller amines
34,47], as nicely reviewed in [31]. Amine release is also com-
on in MS2 fragmentations of oligopeptides, though through
ifferent pathways, as for instance the y7 fragmentation of the
ioactive octapeptide Angiotensin II, corresponding to loss of
he N-terminal Asp residue as 3-aminodihydrofuran-2,5-dione.
he remaining heptapeptide is thus released, where Arg is the
ew N-terminal residue, having its -amino group now free
49].
The behavior of compounds4 at the four different NCE values
ested can be illustrated with data obtained for compound 4.4 as
ompared to that of the parent drug (PQ,1). At NCE = 20%, some
ragmentation is already observed for 1 (MW, 260 g mol−1) with
ragments at m/z 243 and 175, respectively due to loss of the
erminal primary amino group (as ammonia) and of the whole
liphatic chain linked to the 8-amino group yielding MAQ (5).
es 7 in MS4 analyses [X = Y = –H or X and Y = –(CH2)n– with n = 2, 3, 4 or X
N. Vale et al. / International Journal of Mass Spectrometry 270 (2008) 81–93 89
Fig. 2. MSn spectra for imidazolidin-4-one 4.17; main fragmentations are shown on the right.
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ncreasing NCE to 30% leads to complete destruction of PQ,
hose quasi-molecular ion at m/z 260 is no longer observable.
he behavior of PQ in the course of our experiments is again
onfirmed previous findings by LC/ESI-MS analysis reported by
rondz et al. [10]. In what concerns compound 4.4, fragmen-
ation (loss of MAQ) is only detected at NCE ≥ 30%. Anyway,
s already mentioned in Section 3.1, the different behavior of
ompounds 1 and 3.2, due to their higher retention by the fused
ilica capillary as compared to compounds 4, led us to con-
ider the relative abundance of the common MAQ fragment (5)
t NCE = 30% (Table 3) as a more suitable parameter to com-
are relative stabilities of these compounds. Hence, while the
elative abundance of MAQ detected at NCE = 30% is seldom
igher than 10% for compounds 4, it rises up to 35% for PQ
1) and to 58% for 3.2. Once more, the remarkable stability of
midazoldin-4-ones 4 is here outlined, as compared to those of
heir -aminoamide (3) and PQ (1) precursors. Again, this coin-
ides with the distinctive behavior of these compounds under
ompletely different conditions, i.e., hydrolysis in either buffer
r plasma at physiological pH and temperature [41,42].
p
i
f
p
ig. 3. Additional fragmentations observed for ions 7.3–7.20 in the MS4 mode (see t
n a.m.u.ass Spectrometry 270 (2008) 81–93
Other PQ-derived imidazolidin-4-ones were seen to be highly
table in the course of these ESI-MS2 experiments, namely
QValC5 (4.7), all three derivatives of 4-methylcyclohexanone
4.10–4.12) and, specially, PQIleC7 (4.15). The main, and prac-
ically only, fragmentation of 4.7 corresponds to loss of MAQ,
as happens in all other cases, and relative abundance of the
riginal protonated species [M + H]+ is ca. 28% (Table 3) that
s clearly lower than that measured for 4.15 (44%). However,
n this latter case, a higher number of fragments can be identi-
ed, showing that more fragmentation paths are followed, even
hough to a very small extent.
Taken together, these observations show that the
midazolidin-4-one ring in compounds 4 is remarkably
table, as at NCE values as high as 40% the main fragmentative
henomenon is the cleavage of the N–C bond that links
he PQ’s 8-amino group and the aliphatic chain, while the
entagonal ring is left intact. Thus, we can affirm that the
midazolidin-4-one ring is highly stable even under harsh
ragmentative conditions that lead to bond breaking in other
arts of the molecular structure. As previously referred, these
ext); arrows point towards the expelled fragment and corresponding mass loss
N. Vale et al. / International Journal of Mass Spectrometry 270 (2008) 81–93 91
Fig. 4. MSn spectra for imidazolidin-4-one 4.1; main fragmentations are shown on the right.
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ompounds are also remarkably stable towards hydrolysis under
hysiological conditions, which may become an advantage
n terms of bioavailability, as imidazolidin-4-ones 4 have
resented relevant biological activity against rodent malaria
40–42,50].
.3. ESI-MSn analysis at NCE=30%
As described in Section 3.2, fragmentations occur on com-
ounds 4 only at 30% and higher NCE values. Thus, to carry
ut a full study of the fragmentation mechanisms of the PQ-
erived imidazolidin-4-ones, we have fixed the NCE at 30%
nd performed an extended MSn analysis, as detailed in Section
.2.
MS2 analysis at NCE = 30% has been covered in Section 3.2
nd will be no further discussed. As already mentioned, the main
ragment observed in all MS2 spectra of compounds 4 corre-
ponded to loss of MAQ, yielding structure 6 (Scheme 2) that
as selected for MS3 fragmentation. The original species (6)
as still observed as the base peak in the MS3 mode, except
or compound 4.8, where the base peak was generated by loss
f 113 atomic mass units (a.m.u.). In fact, for 16 out of the
0 imidazolidin-4-ones 4 only such fragmentation was signif-
cant in the MS3 mode, i.e., loss of 113 a.m.u. was invariably
bserved. Hence, the most relevant imidazolidin-4-one fragmen-
ation pathway in the MS3 mode corresponds to ring opening
ith expulsion of the original PQ’s aliphatic chain having its
erminal amine still linked to the amino acid’s carbonyl. This
ields ion (R2)(R3)C+–N CHR1 (7) as the detected species
Scheme 3A).
The only four cases where MS3 fragmentation yielded frag-
ents other than 7 derived from compounds 4.1, 4.2, 4.13 and
.16, all of them bearing either Ala or Gly as the amino acid
nd either acetone or cyclohexanone as the ketone moieties.
n the case of cyclohexanone-derived compounds (4.13 and
.16), only one additional fragment was observed due to loss
f the original PQ’s aliphatic chain retaining its terminal amine,
ielding (R2)(R3)C+–N CHR1–CHO as the detected ion (8,
cheme 3B). This ion was also observed in the MS3 spectra
f the acetone-derived compounds (4.1 and 4.2), but these also
xhibited one other relevant fragmentation, probably due to loss
f 1,3-butadiene from the linear side chain, with formation of
he acyclic ion 9 (Scheme 3B). Actually, this was the fragment
9.1: R1 H, R2 R3 Me, m/z = 127) with highest relative abun-
ance in the MS3 spectrum of 4.1. It is noteworthy that these
dditional fragmentations were not observed for other acetone-
r cyclohexanone-derived compounds, which again reflects a
igher instability for structures containing Ala or Gly under the
nalysis conditions. Such behavior is once more coincidental
ith the reactivity of imidazolidin-4-ones 4 towards hydrolysis
41,42].
Given the above described, and except for 4.1, all MS4
ragmentations were carried out from the isolated peak due to
he MS3-generated ions 7 (Scheme 3), from now on labeled
s 7.1–7.20 according to the numbering of their precursor
ompounds 4. Fragmentation of ion 7.2 (R1 R2 R3 Me in
cheme 2) did not lead to any detectable species probably
s
M
bass Spectrometry 270 (2008) 81–93
ecause these, if any, had m/z values lower than 50 a.m.u., which
s the lower limit of the spectral window in the instrumentation
sed. For the remaining cases, a variable number of fragments
as detected, depending on the parent species 7. The most com-
on (and often most abundant) species detected in the MS4
ode corresponded to loss of 17 or 16 a.m.u. (depending on the
etected species being an [M + H]+ or an M+ ion). Those values
re intuitively associated to expulsion of ammonia or methane,
espectively. Both these molecules can only be expelled from
ons 7 through considerable structural rearrangement, as for
nstance those depicted in Scheme 4.
Considerable bond breaking and bond making would have to
ccur, inclusively through cyclic intermediates (Scheme 4A, for
H3 loss) which may appear a bit too farfetched. Loss of a small
mine involving formation of a new cyclic species has been also
escribed for MS2-fragmentation of nicotine, but in such case the
athway for methylamine release with concomitant formation
f 7,8-dihydroquinoline is considerably simpler than the one
llustrated in Scheme 4A [34]. Notwithstanding, the loss of 17
r 16 a.m.u. is the major fragmentation of ions 7 independently
f the nature of R1, R2 and R3, and most of the carbon skeletons
f these three substituents must still be present in the final MS4-
etected ions, whatever these might be.
Additional MS4-generated fragments were commonly asso-
iated to expulsion of part or whole of the amino acid side
hain, as illustrated in Fig. 2 for 4.17 and summarized for all
ompounds in Fig. 3. Species derived from the amino acids
le (7.6, 7.15, 7.18) and Phe (7.4, 7.20) were those suffering
ewer fragmentations in the MS4 mode, with 7.4 decomposing
olely by the loss of 17 (or 16) a.m.u. described in the pre-
ious paragraph. Generally, data were compatible with C–C
ond breaking occurring at either the right or the left side of
he N C double bond in structures 7. Exceptions were regis-
ered for Ile- and Leu-derived structures 7.14, 7.15, 7.17 and
.18, where minor fragments in the MS4 spectra were com-
atible with breaking of the N C bond and departure of the
mino acid side chain attached to its -carbon. Fragmentations
t the R2/R3 substituents were observed for some compounds,
ut never for acetone- or cyclohexanone-derived ions, thus sug-
esting a higher stability in these structures.
In the particular case of 4.1, its main MS3-generated frag-
ent (9.1, Scheme 3B) was used to carry on with the MS4
nalysis. This led to main fragments at m/z = 98 and m/z = 70,
espectively formed upon loss of methanimine (29 a.m.u.) and
-methyleneformamide (57 a.m.u.), as depicted in Fig. 4.
. Concluding remarks
ESI-MSn studies on primaquine-derived imidazolidin-4-
nes, some of which with proven antimalarial activity, were
uccessfully performed. These studies allowed to confirm the
emarkable stability of the imidazolidin-4-one ring under the
ighly fragmentative conditions of experiments in the nozzle-
kimmer region and to propose fragmentation pathways from
S2 to MS4 analysis at NCE = 30%.
Despite the conditions and compound degradation pathways
eing completely different between hydrolysis at physiological
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H/T and ESI-MSn fragmentations, we observed some paral-
elism of the behavior of some of the title compounds both in
he nozzle-skimmer region and in ESI-MS2 analyses, with their
reviously reported reactivity in both isotonic buffer and human
lasma. It would be interesting to determine the reactivity of
he entire family of compounds 4 towards hydrolysis and to
ompare data thus obtained with results from these ESI-MSn
tudies. The finding of a correlation, though unlikely, would be
emarkable and have important implications in drug analysis and
evelopment.
The ESI-MSn characterization of this family of 8-amino-
uinolinic imidazolidin-4-ones showed a common behavioral
attern, where MS2 fragmentation invariably led to detach-
ent of the aromatic heterocyclic core of primaquine,
-methoxy-8-aminoquinoline, leaving the imidazolidin-4-one
ycle untouched. This only suffered fragmentation in the course
f further analyses in the MS3 and MS4 modes, where main
ragmentation types were again common to most compounds.
To the best of our knowledge, this is the first report on stud-
es of this nature centered on structures such as those of the
itle compounds and will hopefully serve as a guide for future
esearch focused on molecules bearing similar structural motifs.
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